Global Erythropoietin Stimulating Agents Market - Segmented by Type, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4520175
  • Report
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • 3SBIO INC.
  • AMGEN
  • BIOCON
  • BIOSIDUS
  • CELLTRION
  • HOFFMANN LA ROCHE
  • MORE
The global erythropoietin stimulating agents market is estimated to grow at a CAGR of about 8.3% during the forecast period. Erythropoietin stimulating agents are the drugs which are similar to erythropoietin. This agent stimulates the growth of red blood cells (RBC). Erythropoietin-stimulating agents are approved for the treatment of anemia due to chronic kidney failure (CKD), chemotherapy, HIV, and also for the reduced RBC during critical surgical procedures.

Increasing Incidence and Prevalence of Anemia

Over the past decade, anemia has emerged as one of the serious diseases related to nutrition, accompanied by increased morbidity and mortality. In major developing countries, neonatal and maternal mortality accounted for 3.0 million deaths, in 2013, and are important contributors to global mortality. Furthermore, about 90,000 deaths have been estimated in all genders and age groups, due to iron anemic deficiency. In 2013, WHO estimated that pregnant women (38%), non-pregnant women (29%), children (43%), and women of reproductive age (29%) suffer from anemia, corresponding to 496 million non-pregnant women, 273 million children and 32 million pregnant women, across the world. And even the chronic infections, including tuberculosis, malaria, HIV, and cancer can also lower blood Hb concentrations. All the above factors, like increased mortality, iron deficiency, and insufficient RBC production, are the major factors driving the erythropoietin stimulating agents market. The other factors, like increasing applications in HIV, end-stage renal disorder, and the risks of thrombosis during surgery and pure red cell aplasia, are driving the market.

Stringent Regulatory Scenario

Erythropoietin (EPO) has to be produced in mammalian cells, as microbes, such as bacteria and yeast, do not have the required cellular machinery. Due to the cell complexity, clinical investigation biologics involve special considerations. In the United States, biologics are approved under Public Health Service Act (PHSA), under which, originator biologics receive approval through 351(a) pathway (Biologics License Application (BLA)). The other factors, such as the continuous need of wireless communication mode and emerging economies, are restraining the market growth. Even approval of biosimilar EPO requires 351(k) pathway, for which, reference biologic is already approved through a BLA or the 351(a) pathway. The United States has adopted a regulatory process for biologics and biosimilars from Europe. Furthermore, a stringent regulatory scenario exists in developing countries as well. These strict regulatory guidelines are hindering the erythropoietin agents market. The other factor that is also restraining the market growth is the adverse effects of the erythropoietin agents.

Asia-Pacific is expected to grow at the Highest CAGR

Asia-Pacific region is expected to grow at the highest CAGR, during the forecast period. Because of the emerging economies and new product launches with better efficacy, it will be a big opportunity for the erythropoietin stimulating agents market.

North America region holds the largest market share, followed by Europe, in the forecast period.

Key Developments in the Market
  • June 2017: Johnson & Johnson completed the acquisition of Actelion.
  • January 2017: Amgen made an agreement with DaVita, for new sourcing and supply.
Major Players: 3SBIO INC., AMGEN, HOFFMANN LA ROCHE, JOHNSON & JOHNSON, BIOSIDUS, BIOCON, HOSPIRA, INTAS PHARMACEUTICALS, CELLTRION, and TEVA PHARMACEUTICALS INDUSTRIES, amongst others

Reasons to Purchase the Report
  • Current and future market outlook for erythropoietin stimulating agents, in the developed and emerging markets
  • Analyze various perspectives of the market, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth, during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the market estimate sheet (in excel)
Customization of the Report

This report can be customized to meet your requirements.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBIO INC.
  • AMGEN
  • BIOCON
  • BIOSIDUS
  • CELLTRION
  • HOFFMANN LA ROCHE
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence and Prevalence of Anemia
6.1.2 Applications in HIV and End-stage Renal Disorder
6.1.3 Risks of Thrombosis during Surgery and Pure Red Cell Aplasia
6.2 Market Restraints
6.2.1 Stringent Regulatory Guidelines
6.2.2 Adverse Side Effects
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 Segmentation -by Type
7.1.1 Epoetin - Alfa
7.1.2 Epoetin - Beta
7.1.3 Epoetin - Omega
7.1.4 Epoetin - Delta
7.1.5 Darbepoetin - Alpha
7.1.6 Others
7.2 Segmentation -by Application
7.2.1 Cancer Chemotherapy
7.2.2 Renal Disorders
7.2.3 Anti-retroviral treatment
7.2.4 Neural diseases
7.2.5 Others
7.3 Segmentation - by Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 New Zealand
7.3.3.6 South Korea
7.3.3.7 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 3SBio Inc.
9.2 Amgen
9.3 Hoffmann La Roche
9.4 Johnson & Johnson
9.5 BioSidus
9.6 Biocon
9.7 Pfizer
9.8 Intas Pharmaceuticals
9.9 Celltrion
9.10 Teva Pharmaceuticals Industries
9.11 Others

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3SBIO INC.
  • AMGEN
  • HOFFMANN LA ROCHE
  • JOHNSON & JOHNSON
  • BIOSIDUS
  • BIOCON
  • HOSPIRA
  • INTAS PHARMACEUTICALS
  • CELLTRION
  • TEVA PHARMACEUTICALS INDUSTRIES.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll